Nuvilex is on the cusp on achieving tremendous advances with respect to the Company’s intellectual property portfolio and clinical trial development. For the record, Nuvilex owns exclusive worldwide rights to a ground-breaking targeted drug delivery system that may be used to develop treatments for many different types of cancer. For example, the pancreatic cancer treatment market alone is in excess of $1Billion and given the potential to use the therapy to treat other cancers, Nuvilex is a pure-play cancer treatment opportunity. In addition, there are indications that the “live-cell encapsulation technology” used in Nuvilex’s pancreatic cancer treatment can be used to treat diabetes. In this regard, Nuvilex is nearing closure of a deal to secure the technology for diabetes as well, substantially increasing the size of the market opportunity for the Company and having many shots on goal.
In related industry news, just last month, Celgene was awarded FDA approval for its pancreatic cancer treatment despite demonstrating only an incremental increase in median survival time and one-year survival rate compared to the single-agent standard of care, gemcitabine, when its drug Abraxane was used in conjunction with gemcitabine. Investors can expect to get a glimpse of how Celgene is deploying the new product which should provide Nuvilex investors with intelligence as to what to expect if the Nuvilex treatment ultimately reaches this milestone. On this note, results for highly successful Phase II clinical trials using this technology to treat advanced, inoperable pancreatic cancer included a median survival time and one-year survival rate superior to those reported for any of the three chemotherapeutic pancreatic cancer treatments approved to date. Moreover, the striking results in the Phase II trials employing the live-cell encapsulation technology were achieved using low chemotherapy doses, which markedly reduced the side effects from the cancer drug.
Penny Stocks are higher risk but inexpensive stocks that trade for less than $5 via “Pink Sheets.” One of the MOST important and potentially profitable things a savvy trader can do is get their hands on relevant and up-to-date information about a company’s operation, goals and impending achievements. When an investor can buy and sell stocks prudently, they can potentially make massive profits by trading these fundamentally strong penny stocks. Currently, penny stocks are becoming more and more popular as traders of all ages and skill levels are testing the waters in trading and purchasing these risky, but potentially lucrative investments. At StockBrain.com we conduct extensive research daily on various companies and alert our subscribers to the ones that have all the indicators of explosive potential. Our #1 priority at StockBrain.com is YOUR success! YOUR success in trading is what helps build our business! We will never fill your inbox with “filler” emails, and we won’t waste your time with companies who “might” break out. We will only send you what we have deemed to be the best of the best and have the highest possibilities for explosive growth and returns! Why wait? Subscribe now to start receiving these valuable newsletters today!
Disclaimer and Terms of Service
The use of research materials published by Stockbrain.com is done at your own risk. You are encouraged to do your own research and due diligence before making any investment decision with respect to the security discussed herein. Stockbrain.com has not been paid by any party in connection with the publication of these materials. You should assume that as of the publication date of this report or letter, Stockbrain.com, (possibly along with or through our owners, affiliates, employees and/or “consultants”) (collectively referred to as Stockbrain) has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our report. Following the publication of any report or letter, Stockbrain intends to continue engaging in transactions in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we reserve the right to buy or sell all or part of our position at any time without notice. This practice could result in our selling securities at any time before, during, or after the publication of this report.
You understand that no content published on this site is intended to constitute a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that Stockbrain is not providing you advice that it believes to be suitable for you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to your specific investment needs. You further understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the site will not contain a list or description of all relevant risk factors relating to a particular security. In addition, you understand that some of the stocks about which content is published on the site have a low market capitalization and/or small public float. Such stocks are therefore subject to more risk than stocks of larger companies. These risks include greater volatility, lower liquidity and less publicly available information.